With the knowledge that B cells also express the receptors of PD1/PDL1/CTLA4 (Kim et al., 2021) and have been established as a favorable prognostic marker in NSCLC (Germain et al., 2014), there exists a theoretical basis for B cells to respond to immune checkpoint inhibitors. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.